Good market uptake for Simeprevir during the first quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a good market uptake and strong sales development for simeprevir during the first quarter 2014. In light of this, Johnson & Johnson and Medivir are now disclosing the simeprevir sales in conjunction with Johnson & Johnson’s first quarter report 2014.

The global first quarter sales (Net sales) of simeprevir amounted to 354 MUSD, of which 291 MUSD were sales in the USA. Medivir’s royalties based on these sales amounted to 162 MSEK (18 MEUR) for the first quarter.

“We are looking forward with confidence to a continued good sales development for simeprevir and the increasing royalty revenue according to our license agreement“, said Maris Hartmanis, Medivir’s CEO.

Medivir will publish its first quarter report on May 8, 2014.

Medivir will host a short telephone conference today.

Conference call

Date: 15 April 2014
Time: 14.45 (CET)

Phone numbers for participants from:

England +44 (0)20 707 532 17
US +1 866 565 2905
Sweden +46 (0)8 619 75 30
Code 946208#

For more information please contact:

Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.55 CET on 15 April 2014.

About Simeprevir

Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.

Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C and the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic HCV. This application is under review by the EMA.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.


About Us

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list.


Documents & Links